RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism

References

• Lemonnier F, Gaulard P, de Leval L. New insights in the pathogenesis of t-cell lymphomas. Curr Opin Oncol. 2018;30(5):277–15. doi:10.1097/CCO.0000000000000474.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Nicolae A, Pittaluga S. Peripheral t-cell and nk-cell lymphomas in the who classification: pearls and pitfalls. Mod pathol. 2013;26(Suppl 1):S71–87. doi:10.1038/modpathol.2012.181.
   PubMed Web of Science ®Google Scholar
• de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic t-cell lymphoma. Br J Haematol. 2010;148(5):673–689. doi:10.1111/j.1365-2141.2009.08003.x.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, Baglin A-C, Haioun C, Delfau-Larue M-H, Gaulard P, et al. Expression of cxcl13 by neoplastic cells in angioimmunoblastic t-cell lymphoma (aitl): a new diagnostic marker providing evidence that aitl derives from follicular helper t cells. Am J Surg Pathol. 2006;30(4):490–494. doi:10.1097/00000478-200604000-00009.
   PubMed Web of Science ®Google Scholar
• Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Expression of cxcl13, a chemokine highly upregulated in germinal center t-helper cells, distinguishes angioimmunoblastic t-cell lymphoma from peripheral t-cell lymphoma, unspecified. Mod pathol. 2006;19(8):1101–1107. doi:10.1038/modpathol.3800625.
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, et al. The gene expression profile of nodal peripheral t-cell lymphoma demonstrates a molecular link between angioimmunoblastic t-cell lymphoma (aitl) and follicular helper t (tfh) cells. Blood. 2007;109(11):4952–4963. doi:10.1182/blood-2006-10-055145.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from t follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67(22):10703–10710. doi:10.1158/0008-5472.CAN-07-1708.
   PubMed Web of Science ®Google Scholar
• Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, et al. A targeted mutational landscape of angioimmunoblastic t-cell lymphoma. Blood. 2014;123(9):1293–1296. doi:10.1182/blood-2013-10-531509.
   PubMed Web of Science ®Google Scholar
• Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee J-E, et al. A recurrent inactivating mutation in rhoa GTPase in angioimmunoblastic t cell lymphoma. Nat Genet. 2014;46(4):371–375. doi:10.1038/ng.2916.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Amador C, McKeithan TW, Chan WC. Molecular and genomic landscape of peripheral t-cell lymphoma. Cancer Treat Res. 2019;176:31–68.
   PubMedGoogle Scholar
• Butzmann A, Sridhar K, Jangam D, Kumar J, Sahoo MK, Shahmarvand N, Warnke R, Rangasamy E, Pinsky BA, Ohgami RS, et al. A comprehensive analysis of rhoa mutation positive and negative angioimmunoblastic t-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. Int J Mol Med. 2020;46(4):1466–1476. doi:10.3892/ijmm.2020.4686.
   PubMed Web of Science ®Google Scholar
• Zang S, Li J, Yang H, Zeng H, Han W, Zhang J, Lee M, Moczygemba M, Isgandarova S, Yang Y, et al. Mutations in 5-methylcytosine oxidase tet2 and rhoa cooperatively disrupt t cell homeostasis. J Clin Invest. 2017;127(8):2998–3012. doi:10.1172/JCI92026.
   PubMed Web of Science ®Google Scholar
• Cortes JR, Ambesi-Impiombato A, Couronné L, Quinn SA, Kim CS, da Silva Almeida AC, West Z, Belver L, Martin MS, Scourzic L, et al. Rhoa g17v induces t follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(259–273.e7):259–273.e7. doi:10.1016/j.ccell.2018.01.001.
   PubMedGoogle Scholar
• Ng SY, Brown L, Stevenson K, deSouza T, Aster JC, Louissaint A, Weinstock DM. Rhoa g17v is sufficient to induce autoimmunity and promotes t-cell lymphomagenesis in mice. Blood. 2018;132(9):935–947. doi:10.1182/blood-2017-11-818617.
   PubMed Web of Science ®Google Scholar
• Lee GJ, Jun Y, Yoo HY, Jeon YK, Lee D, Lee S, Kim J. Angioimmunoblastic T-cell lymphoma-like lymphadenopathy in mice transgenic for human RHOA with p.Gly17Val mutation. Oncoimmunology. 2020;9(1):1746553. doi:10.1080/2162402X.2020.1746553.
   PubMed Web of Science ®Google Scholar
• Bacchetti T, Ferretti G, Sahebkar A. The role of paraoxonase in cancer. Semin Cancer Biol. 2019;56:72–86. doi:10.1016/j.semcancer.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, −2 and −3: what are their functions? Chem Biol Interact. 2016;259:51–62. doi:10.1016/j.cbi.2016.05.036.
   PubMed Web of Science ®Google Scholar
• Witte I, Altenhöfer S, Wilgenbus P, Amort J, Clement AM, Pautz A, Li H, Förstermann U, Horke S. Beyond reduction of atherosclerosis: pon2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011;2(1):e112. doi:10.1038/cddis.2010.91.
   PubMedGoogle Scholar
• Devarajan A, Su F, Grijalva V, Yalamanchi M, Yalamanchi A, Gao F, Trost H, Nwokedi J, Farias-Eisner G, Farias-Eisner R, et al. Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer. Cell Death Dis. 2018;9(3):392. doi:10.1038/s41419-018-0395-2.
   PubMedGoogle Scholar
• Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, Cline G, Kumar P, Cowles RA, Wajapeyee N, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating glut1-mediated glucose transport. Mol Cell. 2017;67(685–701.e6):685–701.e6. doi:10.1016/j.molcel.2017.07.014.
   PubMedGoogle Scholar
• Bacchetti T, Salvolini E, Pompei V, Campagna R, Molinelli E, Brisigotti V, Togni L, Lucarini G, Sartini D, Campanati A, et al. Paraoxonase-2: a potential biomarker for skin cancer aggressiveness. Eur J Clin Invest. 2021;51(5):e13452. doi:10.1111/eci.13452.
   PubMed Web of Science ®Google Scholar
• Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu H-C, Mahfouz R, Raimondi SC, Lenny N, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951–2959. doi:10.1182/blood-2003-01-0338.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F. Peripheral t-cell lymphoma unspecified (ptcl-u): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479. doi:10.1182/blood-2003-09-3080.
   PubMed Web of Science ®Google Scholar
• Chen R, Bélanger S, Frederick MA, Li B, Johnston RJ, Xiao N, Liu Y-C, Sharma S, Peters B, Rao A, et al. In vivo RNA interference screens identify regulators of antiviral cd4(+) and cd8(+) t cell differentiation. Immunity. 2014;41(2):325–338. doi:10.1016/j.immuni.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Patel K, Danilov AV, Pagel JM. Duvelisib for cll/sll and follicular non-Hodgkin lymphoma. Blood. 2019;134(19):1573–1577. doi:10.1182/blood.2019001795.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, et al. Activity of the pi3k-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of t-cell lymphoma. Blood. 2018;131(8):888–898. doi:10.1182/blood-2017-08-802470.
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW, Przychodzen B, Maciejewski JP, Hsi ED. Angioimmunoblastic t-cell lymphomas with the rhoa p.Gly17val mutation have classic clinical and pathologic features. The American. J Surg Pathol. 2016;40(3):335–341. doi:10.1097/PAS.0000000000000555.
   PubMed Web of Science ®Google Scholar
• Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, et al. IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741–1752. doi:10.1182/blood-2015-05-644591.
   PubMed Web of Science ®Google Scholar
• Nguyen PN, Tran NTB, Nguyen TPX, Ngo TNM, Lai DV, Deel CD, Hassell LA, Vuong HG. Clinicopathological implications of rhoa mutations in angioimmunoblastic t-cell lymphoma: a meta-analysis: rhoa mutations in aitl. Clin Lymphoma Myeloma Leuk. 2021;21(7):431–438. doi:10.1016/j.clml.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Joo E, Olson MF, Gerges NZ. Regulation and functions of the rhoa regulatory guanine nucleotide exchange factor gef-h1. Small GTPases. 2020;11(1):1–14. doi:10.1080/21541248.2017.1361898.
   PubMedGoogle Scholar
• Bros M, Haas K, Moll L, Grabbe S. Rhoa as a key regulator of innate and adaptive immunity. Cells. 2019;8(7):733. doi:10.3390/cells8070733.
   PubMed Web of Science ®Google Scholar
• Rougerie P, Delon J. Rho GTPases: masters of t lymphocyte migration and activation. Immunol Lett. 2012;142(1–2):1–13. doi:10.1016/j.imlet.2011.12.003.
   PubMed Web of Science ®Google Scholar
• Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene. 2000;19(1):13–20. doi:10.1038/sj.onc.1203259.
   PubMed Web of Science ®Google Scholar
• Harriague J, Bismuth G. Imaging antigen-induced pi3k activation in t cells. Nat Immunol. 2002;3(11):1090–1096. doi:10.1038/ni847.
   PubMed Web of Science ®Google Scholar
• Manco G, Porzio E, Carusone TM. Human paraoxonase-2 (pon2): protein functions and modulation. Antioxidants. 2021;10(2):256. doi:10.3390/antiox10020256.
   Web of Science ®Google Scholar
• Tsegaye MA, Schafer ZT. Collapsing the metabolic pon2zi scheme in pancreatic ductal adenocarcinoma. Trends Cell Biol. 2017;27(11):785–786. doi:10.1016/j.tcb.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Sukketsiri W, Porntadavity S, Phivthong-ngam L, Lawanprasert S. Lead inhibits paraoxonase 2 but not paraoxonase 1 activity in human hepatoma hepg2 cells. J Appl Toxicol. 2013;33(7):631–637. doi:10.1002/jat.1789.
   PubMed Web of Science ®Google Scholar
• Campagna R, Bacchetti T, Salvolini E, Pozzi V, Molinelli E, Brisigotti V, Sartini D, Campanati A, Ferretti G, Offidani A, et al. Paraoxonase-2 silencing enhances sensitivity of a375 melanoma cells to treatment with cisplatin. Antioxidants. 2020;9(12):1238. doi:10.3390/antiox9121238.
   Web of Science ®Google Scholar
• Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene tfpi2 in prostate carcinoma. Cancer Genomics Proteomics. 2010;7:51–60.
   PubMedGoogle Scholar
• Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN. Pon2 subverts metabolic gatekeeper functions in b cells to promote leukemogenesis. Proc Natl Acad Sci U S A. 2021;118(7):e2016553118.
   PubMed Web of Science ®Google Scholar
• Hui PY, Chen YH, Qin J, Jiang XH. Pon2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia. Hematology. 2022;27(1):32–42. doi:10.1080/16078454.2021.2009643.
   PubMed Web of Science ®Google Scholar
• Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia. Blood. 2010;115(7):1394–1405. doi:10.1182/blood-2009-05-218560.
   PubMed Web of Science ®Google Scholar
• Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, Schwindel U, Zheng C, Müller MC, Gretz N, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006;20(8):1400–1407. doi:10.1038/sj.leu.2404270.
   PubMed Web of Science ®Google Scholar